{"id":322693,"date":"2019-01-28T13:21:02","date_gmt":"2019-01-28T13:21:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=322693"},"modified":"2019-01-28T13:21:02","modified_gmt":"2019-01-28T13:21:02","slug":"creative-biolabs-provides-customized-cart-preclinical-in-vivo-assay-services-based-on-cellrapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-provides-customized-cart-preclinical-in-vivo-assay-services-based-on-cellrapeutics_322693.html","title":{"rendered":"Creative Biolabs Provides Customized CAR-T Preclinical In Vivo Assay Services Based on CellRapeutics\u2122"},"content":{"rendered":"

New York, US–Jan 28, 2019 <\/strong>Based on the CellRapeutics™ platform, Creative Biolabs provides customized and reliable CAR-T in vivo <\/em>preclinical testing<\/a> services for clients across the world, aiming to facilitate CAR-T development and evaluation projects with far less time and budget.<\/p>\n

 <\/p>\n

In vivo<\/em> assessment plays a pivotal role in investigating CAR-T cells efficacy that is closely related to the approaches of delivering CAR genes into T cells, the in vitro <\/em>culture conditions, the constituents of the CAR construct, and the types of host T cells. Although many clinical trials have proved the capability of CAR-T cells to recognize various tumor-associated antigens (TAAs), multiple potential risks such as cytokine storm have also posed a challenge for CAR-T cell clinical application. Therefore, preclinical in vivo<\/em> assessments of the efficacy and safety of CAR-T cells are indispensable for dosage determination and risk managements to reduce the side effects of CAR-T immunotherapy<\/a>.<\/p>\n

 <\/p>\n

“Our one-stop service covers all aspects from cell biology to animal tests with a special emphasis on the construction of tumor xenograft models. Various CAR-T cell preclinical in vivo<\/em> assays are performed in xenograft murine models derived by well-defined cell lines or primary human tumor cells. Owing to the lack of effective innate immunity for the absence of B cells, T cells, or NK cells, immunodeficient mice are our optimal animal models for engraftment of tumor cells and evaluation of CAR-T cells.” said a scientist from Creative Biolabs.<\/p>\n

 <\/p>\n

“In vivo<\/em> assay services in other species are also available, such as non-human primate (NHP). With many well-designed tests, we can detect the progression and remission of tumor cells in any body part throughout the whole treatment duration, obtaining an unambiguous evaluation of the therapeutic efficacy of CAR-T cells. Meanwhile, we conduct a series of studies to investigate several potential safety concerns of CAR-T therapy including inappropriate immune activation (cytokine level), the potential for tumorigenicity, the risks of the delivery procedure, etc<\/em>.”<\/p>\n

 <\/p>\n

With a comprehensive platform and advanced technologies, Creative Biolabs can customize any steps of one-stop CAR-T development and systematically study the in vivo<\/em> expansion, survival, persistence, migration, and distribution of the CAR-T cells, by complying with Good Laboratory Practice (GLP), which is essential for IND application. If you need more information, please visit https:\/\/www.creative-biolabs.com\/car-t\/<\/a>. Experienced scientists in Creative Biolabs will assist you in designing the research program that best suits your purpose and advance your CAR-T cell therapy through clinical trials.<\/p>\n

 <\/p>\n

About Creative Biolabs<\/p>\n

As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, the established leading experts in TCR and CAR T&NK cell immune therapy development offer the one-stop custom services that cover the entire new drug development pipeline, and an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, a unique unparalleled CAR construction and production platform has been built up for all four CAR generations.<\/p>\n

 <\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs
Contact Person:<\/strong> Candy Swift
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.creative-biolabs.com\/car-t\/<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

New York, US–Jan 28, 2019 Based on the CellRapeutics™ platform, Creative Biolabs provides customized and reliable CAR-T in vivo preclinical testing services for clients across the world, aiming to facilitate CAR-T development and evaluation projects with far less time and budget.   In vivo assessment … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-322693","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/322693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=322693"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/322693\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=322693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=322693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=322693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}